FIGURE 1.
(A) Morphology of diffuse large B-cell lymphoma (DLBCL), CD56+; H&E, 20x; (B) Strong expression of CD56 in DLBCL not otherwise specified (NOS) (tissue microarray), 4x; (C) weak to moderate CD56 expression in DLBCL NOS (tissue microarray), 4x.
TABLE 1.
Clinicopathological characteristics of patients with CD56 positive diffuse large B-cell lymphoma (DLBCL), review of the literature with our series
| Publication | Coun | No of pat | Case No | Sex Age | GC type** | Non-GC type | LN | Extranodal disease and site | Clinical stage | IPI | LDH | Surg | CT and No. of cycles | RT | Response | FU |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kern 199323 | USA | 1 | 1 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Muroi 199817 | Jap | 2 | 1 | M,49 | Yes | Yes | Liver, Spleen, Pericard. Ef. Liver | NA | NA | NA | No | CHOP, NAx | No | PR? | NA | |
| 2 | F,62 | Yes | Yes | NA | NA | NA | No | CHOP, NAx | No | PR? | NA | |||||
| Sekita 199918 | Jap | 1 | 1 | M,16 | Yes | Yes | I | NA | NA | No | CHOP, 6x | No | CR | 10 m | ||
| Hammer 199815 | USA | 4 | 1 | M,51 | NA | NA | Yes | Stomach | NA | NA | NA | NA | NA | NA | NA | |
| 2 | M,69 | NA | NA | No | NA | NA | NA | NA | NA | NA | NA | |||||
| 3 | M,76 | NA | NA | Yes | NA | NA | NA | NA | NA | NA | NA | |||||
| 4 | M,54 | NA | NA | Yes | NA | NA | NA | NA | NA | NA | NA | |||||
| Otsuka 200414 | Jap | 2 | 1 | NA | Yes | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| 2 | NA | Yes | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | ||||
| Weisberger *200611 | 1 | M,41 | Yes | Yes | No | Ileocecal valve | NA | NA | NA | NA | NA | NA | NA | NA | ||
| USA | 10 | 2 | M,52 | Yes | Yes | SpineAbdomen Brain | NA | NA | NA | NA | NA | NA | NA | NA | ||
| 3 | M,54 | Yes | Yes | NA | NA | NA | NA | NA | NA | NA | NA | |||||
| 4 | M,83 | Yes | No | NA | NA | NA | NA | NA | NA | NA | NA | |||||
| 5 | M,49 | Yes | Yes | NA | NA | NA | NA | NA | NA | NA | NA | |||||
| 6 | F,57 | Yes | No | NA | NA | NA | NA | NA | NA | NA | NA | |||||
| 7 | F,69 | Yes | Yes | NA | NA | NA | NA | NA | NA | NA | NA | |||||
| 8 | M,77 | Yes | Yes | NA | NA | NA | NA | NA | NA | NA | NA | |||||
| 9 | M,84 | Yes | Yes | NA | NA | NA | NA | NA | NA | NA | NA | |||||
| 10 | M,77 | No | NA | NA | NA | NA | NA | NA | NA | NA | ||||||
| Isobe 200713 | Jap | 3 | 1 | M,80 | Yes | Yes | Ascites | NA | NA | NA | No | THP-COP, 3x | No | NR | DOD | |
| 2 | F,87 | Yes | No | Ileum | NA | NA | NA | Yes | No | No | CR | 22 m | ||||
| 3 | M,73 | Yes | Yes | Ileum | NA | NA | NA | Yes | R-CHOP, 6x | No | CR | 22 m | ||||
| Chen 201016 | Ch | 1 | 1 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Gomyo 20109 | Jap | 7 | 1 | M,29 | Yes | Yes | Spleen | IIIB | HI | ↑ | No | R-CHOP, aPBSCT | No | CR | A, 24 m | |
| 2 | F,60 | Yes | Yes | WR | IIA | L | N | No | R-CHOP 3x | Yes | CR | A, 50 m | ||||
| 3 | F,22 | Yes | No | WR | IA | L | N | No | CHOP 3x | Yes | CR | A, 57 m | ||||
| 4 | M,64 | Yes | Yes | Pl. Ef, Adr. gl, Submand. gl | IIIA | H | ↑ | No | CHOP 5x | No | CR | D, 4 m | ||||
| 5 | M,63 | Yes | No | Nasal cavity | IA | L | N | No | RCHOP 3x | Yes | CR | (pneumonia) | ||||
| 6 | M,50 | Yes | No | Intra-extradural mass | IA | L | N | No | Res+CHOP 4x | Ye | RCR | A, 43 m | ||||
| 7 | F,45 | Yes | No | Subcutis | IVA | HI | ↑ | No | R-CHOP 8x | sNo | A, 70 mA, 5 m | |||||
| Stacchini 201212 | It | 5 | 1 | M,72 | Yes | Yes | Spleen, Stomach, Pancr. | NA | NA | NA | NA | NA | NA | NA | NA | |
| 2 | M,15 | Yes | Yes | Stomach, Liver | NA | NA | NA | NA | NA | NA | NA | NA | ||||
| 3 | M,71 | Yes | No | Nasopharynx | NA | NA | NA | NA | NA | NA | NA | NA | ||||
| 4 | M,60 | NA | NA | NA | NA | NA | NA | NA | NA | |||||||
| 5 | M,21 | Yes | Yes | No | NA | NA | NA | NA | NA | NA | NA | AWD 12m | ||||
| Gu 201310 | SK | 1 | 1 | F,5 | Yes | WR | I | N | Yes | COPAD, 6x | No | CR | NA | |||
| Liu 20208 | Ch | 1 | 1 | M,14 | Yes, DH | Yes | Nasopharynx | IV | NA | ↑ | No | CTX+CP | No | CR | NA | |
| R-Hyper-CVAD AB | ||||||||||||||||
| R-DA-EPOCH, 6x | ||||||||||||||||
| IT DM+CTB,4x | ||||||||||||||||
| Gasljevic 2022 | Slo | 7 | 1 | F,56 | Yes | Yes | Skeletal muscle | IA | 0 | N | Yes | R-CHOP, 3x | No | CR | A, 63 m | |
| 2 | F,51 | Yes | Yes | Small bowel | IA | 0 | N | No | R-CHOP, 3x | No | CR | A, 73 m | ||||
| 3 | M,57 | Yes | IIA | 0 | ↑ | No | R-CHOP, 6x | No | CR | A, 55 m | ||||||
| 4 | M,56 | Yes, DE | Spleen, Liver, Adrenal gland | IVB | 0 | ↑ | No | R-EPOCH,6x +IT,2x | No | CR | A, 40 m | |||||
| 5 | F,53 | Yes | Yes | IIA | 3 | N | Yes | CHOP, 3x | Yes | CR | A, 62 m | |||||
| 6 | F,30 | Yes | Yes | IVB | 3 | ↑ | No | R-CHOP,8x | Yes | CR | A, 182 m | |||||
| 7 | F,79 | NA | NA | Yes | IVB | 5 | ↑ | No | No | No | NA | DOD |
A = alive; aPBSCT = autologous peripheral blood stem cell transplantation; AWD = alive with disease; Ch = China; CHOP = cyclophosphamide, doxorubicin hydrocloride, vincristine sulfat, prednisone; Coun = country; CP = prednisone; CR = complete response; CT = chemotherapy; CTX = cyclophosphamide; D = dead; DA-EPOCH = etoposide, doxorubicin, vindesine, dexamethasone, cyclophosphamide; DE = double expressor; DOD = dead of disease; F = female; FU = follow-up; Gl = gland; Hyper-CVAD AB = A: cyclophosphamide, vindesine, liposomal doxorubicin, dexamethason, B: methotrexate, cytarabine; IPI = International Prognostic Index; It = Italy; IT = intratechal; Jap = Japan; LN = lymph nodes; M = male; m = months; N = normal; NA = not available; NR = no response; Pancr = pancreas; Pl. E = pleural effusion; PR = partial response; R = rituximab; res = resection; RT = radiotherapy; SK = South Korea; Slo = Slovenia; Submand = submandibular; THP-COP = pirarubicin, cyclophosphamide, vincristine sulfat, prednisone; WR = Waldeyers ring
TABLE 2.
Genetic profile of CD56 positive diffuse large B-cell lymphoma (DLBCL) samples
| Case number in Table 2 | COO IHC | COO AFPL | fusion | variants | VAF (%) | variant classiification | Schmitz et al., 201832 classification | ||
|---|---|---|---|---|---|---|---|---|---|
| gene | nucleotide change | amino acid change | |||||||
| 1 | GCB | GCB | ND | RANBP1 | NM_002882.3:c.23A>G | NP_002873.1:p.(His8Arg) | 13,7 | Uncertain significance | unclassified |
| 2 | GCB | GCB | ND | ND | ND | ND | ND | ND | unclassified |
| 3 | GCB | GCB | ND | CD79B | NM_000626.2:c.587A>T | NP_000617.1:p.(Tyr196Phe) | 49,0 | Pathogenic | EZB |
| CD79B | NM_000626.2:c.568A>G | NP_000617.1:p.(Met190Val) | 50,1 | Uncertain significance | |||||
| EZH2 | NM_001203247.1:c.1922A>G | NP_001190176.1:p.(Tyr641Cys) | 53,7 | Pathogenic | |||||
| MYD88 | NM_001172567.1:c.656C>G | NP_001166038.1:p.(Ser219Cys) | 37,7 | Uncertain significance | |||||
| SH3BP5 | NM_004844.4:c.460G>A | NP_004835.2:p.(Ala154Thr) | 19,3 | Uncertain significance | |||||
| 4 | ABC | ABC | IGH-BCL6 | CD79B | NM_000626.2:c.587A>C | NP_000617.1:p.(Tyr196Ser) | 25,9 | Pathogenic | BN2 |
| SH3BP5 | NM_004844.4:c.460G>A | NP_004835.2:p.(Ala154Thr) | 12,6 | Uncertain significance | |||||
[i] AFPL = Archer SusionPlex lymphoma; COO= cell of origin; IHC = immunohistochemical analyses; ND = not detected; VAF = variant allele freqency;